| Name | Title | Contact Details |
|---|
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Boston Microfluidics (BMF) is dedicated to connecting people to their health by increasing access to diagnostic testing for all people. Our technology is a unique combination of elegant sample processing solutions with an intuitive user interface. We strive to streamline current testing systems with devices that perform complex sample processing steps without the need for trained professionals or specialized laboratory equipment. We also seek to simplify diagnostic tests so that they can be used efficiently at the point of care, or even be available for direct sale to consumers. Above all, BMF works to help provide patients with the information they need to make choices about their health.
BloodSource is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Sacramento, CA. To find more information about BloodSource, please visit www.bloodsource.org
IVX Animal Health is a Saint Joseph, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.